Ishizaki T, Yamamoto T, Itoh R, Yasuda J, Fujita H, Okada H
Dept. of Obstetrics and Gynecology, Gamoucho Hospital.
Gan To Kagaku Ryoho. 1995 Jan;22(1):137-40.
In recent years, we treated recurrent uterine endometrial cancer by combined therapy including CDDP. But in poor cases, like renal failure and such, it is difficult to perform the therapy. Two cases of recurrent uterine endometrial cancer treated earlier with MPA were presently treated with an addition of etoposide. The first case was given etoposide (50 mg/m2/day 4 times for 21 days by oral administration). The target tumor mass was reduced in size, occult blood vanished, and the tumor marker was reduced. The other case was treated with etoposide, 50 mg/body/day for 21 days by oral administration, but because of diarrhea, the dose had to be decreased to 25 mg/body/day every day. The tumor marker was reduced and genital bleeding vanished. These cases suggested that etoposide-MPA combined therapy might be effective for recurrent uterine endometrial cancer of well-differentiated type.
近年来，我们采用包括顺铂在内的联合疗法治疗复发性子宫内膜癌。但对于情况较差的患者，如肾衰竭患者等，实施该疗法存在困难。两例早期接受甲羟孕酮治疗的复发性子宫内膜癌患者，目前加用依托泊苷进行治疗。第一例患者给予依托泊苷（50mg/m²/天，口服，共4次，持续21天）。靶肿瘤体积缩小，潜血消失，肿瘤标志物降低。另一例患者口服依托泊苷，50mg/天，共21天，但因腹泻，剂量不得不减至25mg/天。肿瘤标志物降低，阴道出血消失。这些病例表明，依托泊苷-甲羟孕酮联合疗法可能对高分化型复发性子宫内膜癌有效。
